


Active Filter(s):
Details:
Formulation and stability testing of DMT drug product by CHDR's partner pharmacy has commenced in accordance with projected start date of EBRX-101(N, N-dimethyltryptamine), a study that will evaluate controlled intravenous infusion of population of healthy smokers.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: EBRX-101
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Recipient: Entheon Biomedical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2021